Effects of Psychostimulants and Antipsychotics on Serum Lipids in an Animal Model for Schizophrenia

Correia, Banny Silva Barbosa; Nani, João V.; Ricardo, Raniery Waladares; Stanisić, Danijela; Costa, Tássia Brena Barroso Carneiro; Hayashi, Mirian A. F.; Tasić, Ljubica

doi:10.3390/biomedicines9030235

Cited by 23 publications

(23 citation statements)

References 55 publications

(92 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interesting observations on the level of serum lipids have been made in patients with schizophrenia and in persons using psychostimulants. Decreases in serum lipid levels were observed in both groups ( 3 ). Studies assessing self-perception and assessment of interpersonal space have been performed ( 4 ).…”

Section: Introductionmentioning

confidence: 93%

“…In addition to these clinically important symptoms for the diagnosis of schizophrenia, depressive, anxious, and cognitive symptoms are common if not always present ( 1 ). These psychiatric manifestations are associated with metabolic, lipid, and immune changes, often requiring additional therapeutic approaches ( 2 , 3 ). Interesting observations on the level of serum lipids have been made in patients with schizophrenia and in persons using psychostimulants.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Dissociative Model in Patients With Resistant Schizophrenia

Panov

2022

Front. Psychiatry

View full text Add to dashboard Cite

BackgroundSchizophrenia is a severe mental illness in which, despite the growing number of antipsychotics from 30 to 50% of patients remain resistant to treatment. Many resistance factors have been identified. Dissociation as a clinical phenomenon is associated with a loss of integrity between memories and perceptions of reality. Dissociative symptoms have also been found in patients with schizophrenia of varying severity. The established dispersion of the degree of dissociation in patients with schizophrenia gave us reason to look for the connection between the degree of dissociation and resistance to therapy.MethodsThe type of study is correlation analysis. 106 patients with schizophrenia were evaluated. Of these, 45 with resistant schizophrenia and 60 with clinical remission. The Positive and Negative Syndrome Scale (PANSS) and Brief Psychiatric Rating Scale (BPRS) scales were used to assess clinical symptoms. The assessment of dissociative symptoms was made with the scale for dissociative experiences (DES). Statistical methods were used to analyze the differences in results between the two groups of patients.ResultsPatients with resistant schizophrenia have a higher level of dissociation than patients in remission. This difference is significant and demonstrative with more than twice the level of dissociation in patients with resistant schizophrenia.The level of dissociation measured in patients with resistant schizophrenia is as high as the points on the DES in dissociative personality disorder.ConclusionPatients with resistant schizophrenia have a much higher level of dissociation than patients in clinical remission. The established difference between the two groups support to assume that resistance to the administered antipsychotics is associated with the presence of high dissociation in the group of resistant patients. These results give us explanation to think about therapeutic options outside the field of antipsychotic drugs as well as to consider different strategies earlier in the diagnostic process.

show abstract

Section: Introductionmentioning

confidence: 93%

Section: Introductionmentioning

confidence: 99%

Dissociative Model in Patients With Resistant Schizophrenia

Panov

2022

Front. Psychiatry

View full text Add to dashboard Cite

show abstract

“…There are studies showing that the disorder has numerous intertwined symptoms in the clinical expression as well as some typically psychotic ones with delusions and hallucinations being part of the overall presentation of the disease [1]. Other concomitant changes have also been reported, such as impaired connectivity between neuronal populations, changes in metabolism, the opioid system, and immunological parameters [2][3][4][5]. All these data suggest that schizophrenia is a systemic process in which mental symptoms as clinical presentation are part of the overall picture of the disorder.…”

Section: Introductionmentioning

confidence: 99%

Higher Depression Scores in Patients with Drug-Resistant Schizophrenia

Panov¹

2022

J. Integr. Neurosci.

View full text Add to dashboard Cite

Background: Schizophrenia is a mental illness with diverse clinical presentation, in which a significant proportion of patients show resistance to treatment. In patients with schizophrenia, symptoms from all psychotic and affective spectra are observed. On the one hand, affective symptoms determine the clinical course of schizophrenia and on the other hand, depressive symptoms are some of the most common ones in psychiatry in general. These data give us reason to explore the impact of depressive symptoms on the course of schizophrenia and its relationship with resistance to treatment. Method: A study of 105 patients with schizophrenia was performed. Of these, 39 were male and 66 were female. The evaluation of the effectiveness of the treatment carried out at 12 weeks of therapy showed that 45 were resistant to schizophrenia and the remaining 60 were in clinical remission. The clinical evaluation of the patients was performed with the PANSS (Positive and Negative Syndrome Scale) and BPRS (Brief Psychiatric Rating Scale) scales. The assessment of depressive complaints was conducted with the Hamilton Depression Scale. Results: Our study showed that in the analysis of depressive complaints with the Hamilton scale females got 12.55 points, and males got 11.44 points. We found a correlation of depressive complaints with the evaluation on the PANSS and BPRS scales, and in the analysis on the individual subscales we found a correlation on the subscale for positive and disorganized symptoms and no correlation on the scale for negative symptoms. We established a difference in the level of depression in patients with resistance in whom the level of depressive complaints was 13.82, while in those in clinical remission it was 10.87 points. Conclusions: The level of depressive symptoms in patients with resistant schizophrenia is higher than in clinical remission. Depressive symptoms correlate with positive and disorganized symptoms on the PANSS scale, but not with negative symptoms. Gender is not a determining factor in depressive complaints.

show abstract

“…Unfortunately, treatment and diagnostic methods for these illnesses remain unsatisfactory. It is therefore not surprising that the search for biomarkers is intense [ 3 , 4 , 5 , 6 , 7 , 8 ]. However, a crucial step in the development of biomarkers and improvement of treatment as well as diagnosis for any illness is understanding its pathophysiology.…”

Section: Introductionmentioning

confidence: 99%

Optimization of Neurite Tracing and Further Characterization of Human Monocyte-Derived-Neuronal-like Cells

et al. 2021

View full text Add to dashboard Cite

Deficits in neuronal structure are consistently associated with neurodevelopmental illnesses such as autism and schizophrenia. Nonetheless, the inability to access neurons from clinical patients has limited the study of early neurostructural changes directly in patients’ cells. This obstacle has been circumvented by differentiating stem cells into neurons, although the most used methodologies are time consuming. Therefore, we recently developed a relatively rapid (~20 days) protocol for transdifferentiating human circulating monocytes into neuronal-like cells. These monocyte-derived-neuronal-like cells (MDNCs) express several genes and proteins considered neuronal markers, such as MAP-2 and PSD-95. In addition, these cells conduct electrical activity. We have also previously shown that the structure of MDNCs is comparable with that of human developing neurons (HDNs) after 5 days in culture. Moreover, the neurostructure of MDNCs responds similarly to that of HDNs when exposed to colchicine and dopamine. In this manuscript, we expanded our characterization of MDNCs to include the expression of 12 neuronal genes, including tau. Following, we compared three different tracing approaches (two semi-automated and one automated) that enable tracing using photographs of live cells. This comparison is imperative for determining which neurite tracing method is more efficient in extracting neurostructural data from MDNCs and thus allowing researchers to take advantage of the faster yield provided by these neuronal-like cells. Surprisingly, it was one of the semi-automated methods that was the fastest, consisting of tracing only the longest primary and the longest secondary neurite. This tracing technique also detected more structural deficits. The only automated method tested, Volocity, detected MDNCs but failed to trace the entire neuritic length. Other advantages and disadvantages of the three tracing approaches are also presented and discussed.

show abstract

Effects of Psychostimulants and Antipsychotics on Serum Lipids in an Animal Model for Schizophrenia

Cited by 23 publications

References 55 publications

Dissociative Model in Patients With Resistant Schizophrenia

Dissociative Model in Patients With Resistant Schizophrenia

Higher Depression Scores in Patients with Drug-Resistant Schizophrenia

Optimization of Neurite Tracing and Further Characterization of Human Monocyte-Derived-Neuronal-like Cells

Contact Info

Product

Resources

About